MARKET

IMMP

IMMP

Immutep
NASDAQ
2.790
-0.070
-2.45%
After Hours: 2.790 0 0.00% 16:10 02/20 EST
OPEN
2.860
PREV CLOSE
2.860
HIGH
2.930
LOW
2.780
VOLUME
63.36K
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
1.320
MARKET CAP
411.17M
P/E (TTM)
-10.0613
1D
5D
1M
3M
1Y
5Y
1D
Immutep Publishes Corporate Presentation on LAG-3 Immunotherapy for Cancer and Autoimmune Disease
Reuters · 19h ago
Immutep Initiated at Market Outperform by Citizens
Dow Jones · 4d ago
Immutep Price Target Announced at $6.00/Share by Citizens
Dow Jones · 4d ago
Citizens Initiates Coverage On Immutep with Market Outperform Rating, Announces Price Target of $6
Benzinga · 4d ago
Weekly Report: what happened at IMMP last week (0209-0213)?
Weekly Report · 5d ago
Immutep erreicht 50 % Patientenzahl in globaler TACTI-004 Phase-III-Studie bei Lungenkrebs
Reuters · 02/10 11:03
Immutep Reaches 50% Enrolment in Global Phase III TACTI-004 Lung Cancer Trial
Reuters · 02/10 11:03
Weekly Report: what happened at IMMP last week (0202-0206)?
Weekly Report · 02/09 10:02
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.